ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Anti-inflammatory effect of pirfenidone compared to dexamethasone in ulcerative colitis model induced by acetic acid in rats: involvement of miR-146a and TLR4/NF-κB signaling.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease.BMC gastroenterology · 2026Article
- Detorsion is not innocent: pirfenidone prevents contralateral ovarian damage following ovarian torsion.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic autoimmune inflammatory condition distinguished by tissue damage in colonic mucosal layers. Several pro-inflammatory cytokines are involved in the immunopathogenesis of UC. Multiple studies showed that Toll-like receptor 4 (TLR4) expression markedly increases in UC patients. Thus, concentrating on this pathway may serve as the foundation for novel drug development targeting for treating or impeding the progression of UC. This study aims to explore the effects of pirfenidone (PRF) versus dexamethasone (DEX) on oxidative stress, tissue injury, inflammation, and fibrosis in a rat model of colitis using both biochemical and histopathological analysis. Colitis was induced by administering a single dose of 3% acetic acid (AA) intrarectally. Control animals received injections of an equivalent volume of 0.9% NaCl. Rats were then treated with either 14 days of DEX (2 mg/kg /day; p.o.) or PRF (100 mg/kg/day; p.o.). Animals were sacrificed on day 21 (7 days for acclimatization + 14 days for treatment), and then, the distal 10 cm of each colon was excised. Subsequently, all tissue samples were assessed for macroscopic damage, pathological findings, and different biochemical markers. Both drugs significantly suppressed the elevated levels of inflammatory markers, including TLR4, IL-1β, myeloid differentiation primary response protein 88 (MyD88), Bcl-2-associated X protein (BAX), nuclear factor kappa (NF-κB), tumor necrosis factor-alpha (TNF-α), microRNA-146a (miR-146a), caspase-3, transforming growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and myeloperoxidase (MPO), compared to the untreated UC Group. Additionally, they significantly elevated B-cell lymphoma 2 (BCL2) and platelet-derived growth factor (PDGF) levels, indicating their potential to mitigate inflammation and promote tissue repair. Histologically, PRF and DEX preserved intestinal structure as compared to the control group. PRF is considered a promising and effective anti-inflammatory alternative in the management of rat models of acetic acid-induced colitis.
Indexed as
Identifiers
40960515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.